An oral proteasome inhibitor for multiple myeloma

The Lancet Oncology

Volumn 15, Issue 13, 2014, Pages 1417-1418

  Pratt, Guy ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; IXAZOMIB; LENALIDOMIDE; STEROID; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; GLYCINE; IXAZOMIB CITRATE; PROTEASOME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG COST; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NEUROPATHY; NOTE; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; FEMALE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORON COMPOUNDS; FEMALE; GLYCINE; HUMANS; MALE; MULTIPLE MYELOMA; PROTEASOME INHIBITORS;

EID: 84925230958     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70372-9     Document Type: Note

References (5)

1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014, 28:455-473.
2. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
3. Kortuem KM, Stewart AK Carfilzomib. Blood 2013, 121:893-897.
4. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014, published online Nov 14. http://dx.doi.org/10.1016/S1470-2045(14)71125-8.
5. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011, 118:4519-4529.